The Efficacy and Safety of the new biologic agents (humanized anti-human Interlukin-6 receptor monoclonal antibody) on abnormal lipid metabolism and atherosclerosis for rheumatoid arthritis patients in Japa
Not Applicable
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000001407
- Lead Sponsor
- The First Department of Internal Medicine.University of Occupation & Environmental Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
RA patients who have serious infection patients who have history of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies patients with Primary or secondary immunodeficiency
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adiponectin Remnant like particles-cholesterol Each type of serum cholesterol Carotid echo sonography
- Secondary Outcome Measures
Name Time Method DAS28 Remission rate ACR core set Total Sharp Score